Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...
Zacks.com on MSN6d
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to BuyNovo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...
Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...
Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Fractyl Health, Inc. (GUTS – Research Report). The associated price ...
Zacks.com on MSN6d
LLY Falls Around 14% in 3 Months: How to Play the StockEli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...
Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...
Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...
The FDA is allowing pharmacies to dispense compounded versions of semaglutide and tirzepatide until shortages ... that some may still be available for purchase. An Eli Lilly spokesperson said ...
As certain weight-loss drugs have become increasingly popular, scammers are taking notice and coming out of the woodwork to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback